APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiangiogenic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antiangiogenic Drugs Market Outlook and Growth Opportunities 2026

27 December 2025192 pages

Choose your research edition.

Industry ResearchAntiangiogenic Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiangiogenic Drugs Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Antiangiogenic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiangiogenic Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiangiogenic Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Antiangiogenic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antiangiogenic Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antiangiogenic Drugs market include Chia Tai Tianqing, Sanofi, Jiangsu Hengrui Pharmaceuticals, Simcere, Roche, Pfizer, Novartis, Janssen Biotech and Exelixis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antiangiogenic Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antiangiogenic Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antiangiogenic Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antiangiogenic Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Antiangiogenic Drugs Segment by Company

Chia Tai Tianqing

Sanofi

Jiangsu Hengrui Pharmaceuticals

Simcere

Roche

Pfizer

Novartis

Janssen Biotech

Exelixis

Eli Lilly

Eisai

Boehringer Ingelheim

Bayer

AstraZeneca

Antiangiogenic Drugs Segment by Type

Macromolecular Single-target Angiogenesis Inhibitor

Endogenous Pan-target Angiogenesis Inhibitor

Small Molecule Multi-target Angiogenesis Inhibitor

Antiangiogenic Drugs Segment by Application

Cancer Therapy

Inflammatory and Autoimmune Diseases

Ophthalmic Diseases

Other

Antiangiogenic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antiangiogenic Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antiangiogenic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antiangiogenic Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Antiangiogenic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiangiogenic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiangiogenic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiangiogenic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antiangiogenic Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antiangiogenic Drugs industry.

Chapter 3: Detailed analysis of Antiangiogenic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antiangiogenic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antiangiogenic Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antiangiogenic Drugs Industry Trends Table 2. Antiangiogenic Drugs Industry Drivers Table 3. Antiangiogenic Drugs Industry Opportunities and Challenges Table 4. Antiangiogenic Drugs Industry Restraints Table 5. Global Antiangiogenic Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antiangiogenic Drugs Revenue Share by Company (2021-2026) Table 7. Global Antiangiogenic Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Antiangiogenic Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Antiangiogenic Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Antiangiogenic Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antiangiogenic Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Antiangiogenic Drugs Company, Product Type & Application Table 13. Global Antiangiogenic Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antiangiogenic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Macromolecular Single-target Angiogenesis Inhibitor Table 18. Significant Companies of Endogenous Pan-target Angiogenesis Inhibitor Table 19. Significant Companies of Small Molecule Multi-target Angiogenesis Inhibitor Table 20. Global Antiangiogenic Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Antiangiogenic Drugs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Antiangiogenic Drugs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Antiangiogenic Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Antiangiogenic Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Antiangiogenic Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antiangiogenic Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Antiangiogenic Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Antiangiogenic Drugs Sales Value Share by Type (2021-2026) Table 29. Global Antiangiogenic Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Cancer Therapy Table 31. Significant Companies of Inflammatory and Autoimmune Diseases Table 32. Significant Companies of Ophthalmic Diseases Table 33. Significant Companies of Other Table 34. Global Antiangiogenic Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Antiangiogenic Drugs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Antiangiogenic Drugs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Antiangiogenic Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Antiangiogenic Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Antiangiogenic Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Antiangiogenic Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Antiangiogenic Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Antiangiogenic Drugs Sales Value Share by Application (2021-2026) Table 43. Global Antiangiogenic Drugs Sales Value Share by Application (2027-2032) Table 44. Global Antiangiogenic Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Antiangiogenic Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Antiangiogenic Drugs Sales Market Share by Region (2021-2026) Table 47. Global Antiangiogenic Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global Antiangiogenic Drugs Sales Market Share by Region (2027-2032) Table 49. Global Antiangiogenic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Antiangiogenic Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Antiangiogenic Drugs Sales Value Share by Region (2021-2026) Table 52. Global Antiangiogenic Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Antiangiogenic Drugs Sales Value Share by Region (2027-2032) Table 54. Global Antiangiogenic Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Antiangiogenic Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Antiangiogenic Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Antiangiogenic Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 59. Global Antiangiogenic Drugs Sales Market Share by Country (2021-2026) Table 60. Global Antiangiogenic Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Antiangiogenic Drugs Sales Market Share by Country (2027-2032) Table 62. Global Antiangiogenic Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Antiangiogenic Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Antiangiogenic Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Antiangiogenic Drugs Sales Value Market Share by Country (2027-2032) Table 66. Chia Tai Tianqing Company Information Table 67. Chia Tai Tianqing Business Overview Table 68. Chia Tai Tianqing Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio Table 70. Chia Tai Tianqing Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sanofi Antiangiogenic Drugs Product Portfolio Table 75. Sanofi Recent Development Table 76. Jiangsu Hengrui Pharmaceuticals Company Information Table 77. Jiangsu Hengrui Pharmaceuticals Business Overview Table 78. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio Table 80. Jiangsu Hengrui Pharmaceuticals Recent Development Table 81. Simcere Company Information Table 82. Simcere Business Overview Table 83. Simcere Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Simcere Antiangiogenic Drugs Product Portfolio Table 85. Simcere Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Roche Antiangiogenic Drugs Product Portfolio Table 90. Roche Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Pfizer Antiangiogenic Drugs Product Portfolio Table 95. Pfizer Recent Development Table 96. Novartis Company Information Table 97. Novartis Business Overview Table 98. Novartis Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Novartis Antiangiogenic Drugs Product Portfolio Table 100. Novartis Recent Development Table 101. Janssen Biotech Company Information Table 102. Janssen Biotech Business Overview Table 103. Janssen Biotech Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Janssen Biotech Antiangiogenic Drugs Product Portfolio Table 105. Janssen Biotech Recent Development Table 106. Exelixis Company Information Table 107. Exelixis Business Overview Table 108. Exelixis Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Exelixis Antiangiogenic Drugs Product Portfolio Table 110. Exelixis Recent Development Table 111. Eli Lilly Company Information Table 112. Eli Lilly Business Overview Table 113. Eli Lilly Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Eli Lilly Antiangiogenic Drugs Product Portfolio Table 115. Eli Lilly Recent Development Table 116. Eisai Company Information Table 117. Eisai Business Overview Table 118. Eisai Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Eisai Antiangiogenic Drugs Product Portfolio Table 120. Eisai Recent Development Table 121. Boehringer Ingelheim Company Information Table 122. Boehringer Ingelheim Business Overview Table 123. Boehringer Ingelheim Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio Table 125. Boehringer Ingelheim Recent Development Table 126. Bayer Company Information Table 127. Bayer Business Overview Table 128. Bayer Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Bayer Antiangiogenic Drugs Product Portfolio Table 130. Bayer Recent Development Table 131. AstraZeneca Company Information Table 132. AstraZeneca Business Overview Table 133. AstraZeneca Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. AstraZeneca Antiangiogenic Drugs Product Portfolio Table 135. AstraZeneca Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Antiangiogenic Drugs Distributors List Table 139. Antiangiogenic Drugs Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Antiangiogenic Drugs Product Image Figure 2. Global Antiangiogenic Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiangiogenic Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antiangiogenic Drugs Sales (2021-2032) & (K Units) Figure 5. Global Antiangiogenic Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Antiangiogenic Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Macromolecular Single-target Angiogenesis Inhibitor Image Figure 10. Endogenous Pan-target Angiogenesis Inhibitor Image Figure 11. Small Molecule Multi-target Angiogenesis Inhibitor Image Figure 12. Global Antiangiogenic Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Antiangiogenic Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Antiangiogenic Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Antiangiogenic Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Antiangiogenic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Antiangiogenic Drugs Sales Value Share by Type (2021-2032) Figure 18. Cancer Therapy Image Figure 19. Inflammatory and Autoimmune Diseases Image Figure 20. Ophthalmic Diseases Image Figure 21. Other Image Figure 22. Global Antiangiogenic Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Antiangiogenic Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Antiangiogenic Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Antiangiogenic Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Antiangiogenic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Antiangiogenic Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Antiangiogenic Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Antiangiogenic Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Antiangiogenic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Antiangiogenic Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Antiangiogenic Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Antiangiogenic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Antiangiogenic Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Antiangiogenic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Antiangiogenic Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Antiangiogenic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Antiangiogenic Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Antiangiogenic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Antiangiogenic Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Antiangiogenic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Antiangiogenic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Antiangiogenic Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Antiangiogenic Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Macromolecular Single-target Angiogenesis Inhibitor
  • Endogenous Pan-target Angiogenesis Inhibitor
  • Small Molecule Multi-target Angiogenesis Inhibitor
Applications
  • Cancer Therapy
  • Inflammatory and Autoimmune Diseases
  • Ophthalmic Diseases
  • Other
Companies covered
  • Chia Tai Tianqing
  • Sanofi
  • Jiangsu Hengrui Pharmaceuticals
  • Simcere
  • Roche
  • Pfizer
  • Novartis
  • Janssen Biotech
  • Exelixis
  • Eli Lilly
  • Eisai
  • Boehringer Ingelheim
  • Bayer
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antiangiogenic Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Antiangiogenic Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Antiangiogenic Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antiangiogenic Drugs Market Dynamics
  1. 2.1 Antiangiogenic Drugs Industry Trends
  2. 2.2 Antiangiogenic Drugs Industry Drivers
  3. 2.3 Antiangiogenic Drugs Industry Opportunities and Challenges
  4. 2.4 Antiangiogenic Drugs Industry Restraints
3 Antiangiogenic Drugs Market by Company
  1. 3.1 Global Antiangiogenic Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Antiangiogenic Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Antiangiogenic Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Antiangiogenic Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Antiangiogenic Drugs Company Ranking (2024-2026)
  6. 3.6 Global Antiangiogenic Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Antiangiogenic Drugs Company Product Type and Application
  8. 3.8 Global Antiangiogenic Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antiangiogenic Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antiangiogenic Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antiangiogenic Drugs Market by Type
  1. 4.1 Antiangiogenic Drugs Type Introduction
  2. 4.1.1 Macromolecular Single-target Angiogenesis Inhibitor
  3. 4.1.2 Endogenous Pan-target Angiogenesis Inhibitor
  4. 4.1.3 Small Molecule Multi-target Angiogenesis Inhibitor
  5. 4.2 Global Antiangiogenic Drugs Sales Volume by Type
  6. 4.2.1 Global Antiangiogenic Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antiangiogenic Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Antiangiogenic Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Antiangiogenic Drugs Sales Value by Type
  10. 4.3.1 Global Antiangiogenic Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Antiangiogenic Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Antiangiogenic Drugs Sales Value Share by Type (2021-2032)
5 Antiangiogenic Drugs Market by Application
  1. 5.1 Antiangiogenic Drugs Application Introduction
  2. 5.1.1 Cancer Therapy
  3. 5.1.2 Inflammatory and Autoimmune Diseases
  4. 5.1.3 Ophthalmic Diseases
  5. 5.1.4 Other
  6. 5.2 Global Antiangiogenic Drugs Sales Volume by Application
  7. 5.2.1 Global Antiangiogenic Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Antiangiogenic Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Antiangiogenic Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Antiangiogenic Drugs Sales Value by Application
  11. 5.3.1 Global Antiangiogenic Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Antiangiogenic Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Antiangiogenic Drugs Sales Value Share by Application (2021-2032)
6 Antiangiogenic Drugs Regional Sales and Value Analysis
  1. 6.1 Global Antiangiogenic Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antiangiogenic Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Antiangiogenic Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Antiangiogenic Drugs Sales by Region (2027-2032)
  5. 6.3 Global Antiangiogenic Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antiangiogenic Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antiangiogenic Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antiangiogenic Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Antiangiogenic Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antiangiogenic Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Antiangiogenic Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antiangiogenic Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Antiangiogenic Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antiangiogenic Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antiangiogenic Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antiangiogenic Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Antiangiogenic Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antiangiogenic Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antiangiogenic Drugs Sales Value Share by Country, 2025 VS 2032
7 Antiangiogenic Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Antiangiogenic Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antiangiogenic Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antiangiogenic Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Antiangiogenic Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Antiangiogenic Drugs Sales by Country (2027-2032)
  6. 7.4 Global Antiangiogenic Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antiangiogenic Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antiangiogenic Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antiangiogenic Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antiangiogenic Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antiangiogenic Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing
  2. 8.1.1 Chia Tai Tianqing Company Information
  3. 8.1.2 Chia Tai Tianqing Business Overview
  4. 8.1.3 Chia Tai Tianqing Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Antiangiogenic Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Jiangsu Hengrui Pharmaceuticals
  14. 8.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
  15. 8.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  16. 8.3.3 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio
  18. 8.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  19. 8.4 Simcere
  20. 8.4.1 Simcere Company Information
  21. 8.4.2 Simcere Business Overview
  22. 8.4.3 Simcere Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Simcere Antiangiogenic Drugs Product Portfolio
  24. 8.4.5 Simcere Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche Antiangiogenic Drugs Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Antiangiogenic Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Antiangiogenic Drugs Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Janssen Biotech
  44. 8.8.1 Janssen Biotech Company Information
  45. 8.8.2 Janssen Biotech Business Overview
  46. 8.8.3 Janssen Biotech Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Janssen Biotech Antiangiogenic Drugs Product Portfolio
  48. 8.8.5 Janssen Biotech Recent Developments
  49. 8.9 Exelixis
  50. 8.9.1 Exelixis Company Information
  51. 8.9.2 Exelixis Business Overview
  52. 8.9.3 Exelixis Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Exelixis Antiangiogenic Drugs Product Portfolio
  54. 8.9.5 Exelixis Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Antiangiogenic Drugs Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Eisai
  62. 8.11.1 Eisai Company Information
  63. 8.11.2 Eisai Business Overview
  64. 8.11.3 Eisai Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Eisai Antiangiogenic Drugs Product Portfolio
  66. 8.11.5 Eisai Recent Developments
  67. 8.12 Boehringer Ingelheim
  68. 8.12.1 Boehringer Ingelheim Company Information
  69. 8.12.2 Boehringer Ingelheim Business Overview
  70. 8.12.3 Boehringer Ingelheim Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio
  72. 8.12.5 Boehringer Ingelheim Recent Developments
  73. 8.13 Bayer
  74. 8.13.1 Bayer Company Information
  75. 8.13.2 Bayer Business Overview
  76. 8.13.3 Bayer Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Bayer Antiangiogenic Drugs Product Portfolio
  78. 8.13.5 Bayer Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca Antiangiogenic Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Antiangiogenic Drugs Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antiangiogenic Drugs Value Chain Analysis
  2. 9.1.1 Antiangiogenic Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antiangiogenic Drugs Sales Mode & Process
  6. 9.2 Antiangiogenic Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antiangiogenic Drugs Distributors
  9. 9.2.3 Antiangiogenic Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst